Prezalumab
mAbexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT02391259)
Timeline
Indications
Mechanism of action
- ICOS ligandINHIBITOR
ICOSLG inhibitor
- Inducible T-cell costimulatorINHIBITOR
ICOS inhibitor
- T-lymphocyte activation antigen CD80Supplementation
CD80 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109311 ↗
- ChEMBLCHEMBL2109249 ↗
Also known as
- amg 557
- amg-557
- medi5872
- medi-5872
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02334306 | Phase 2 | Jun 1, 2015 | Amgen, MedImmune, University of California, San Francisco, University of Pittsburgh |
| NCT01683695 | Phase 1 | Jun 1, 2012 | Amgen |
| NCT01493518 | Phase 1 | Nov 1, 2011 | Amgen |
| NCT01389895 | Phase 1 | Oct 1, 2011 | Amgen |
| NCT00774943 | Phase 1 | Dec 1, 2008 | Amgen |
| NCT02391259 | Phase 1 | Nov 1, 2006 | Amgen |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 6 | 5 | 2 | 2006 |
| MedImmune | For profit | 1 | 1 | 1 | 2015 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1